DNMT3A and cyclic hematopoiesis: Patients with CH have a 5–10 times higher risk of developing hematological malignancies than those without CH, and DNMT3A mutations are the most common genetic event in CH, accounting for 40% of all CH cases, regarded as an early, pro-leukemic event.